Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Sodium phosphate, monobasic | The risk or severity of nephrotoxicity can be increased when Enalkiren is combined with Sodium phosphate, monobasic. |
| Valsartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Valsartan. |
| Olmesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Olmesartan. |
| Losartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Losartan. |
| Candesartan cilexetil | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Candesartan cilexetil. |
| Eprosartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Eprosartan. |
| Telmisartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Telmisartan. |
| Irbesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Irbesartan. |
| Forasartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Forasartan. |
| Saprisartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Saprisartan. |
| Tasosartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Tasosartan. |
| Saralasin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Saralasin. |
| Azilsartan medoxomil | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Azilsartan medoxomil. |
| Fimasartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Fimasartan. |
| Candesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Candesartan. |
| Sparsentan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Sparsentan. |